In this week’s edition of InnovationRx, we look at cheaper biologic drugs, Novo Nordisk’s $2 billion next-gen obesity drug deal, new ways of fighting cancer, and more.

Overview Artificial intelligence seems to be transforming drug discovery in 2026, enabling faster molecule design, smarter clinical trials, and reduced R&D ...

Pharma and life sciences GCCs reduce drug development timelines and costs by leveraging AI and automation, enhancing R&D efficiency.

With drug development costs topping $1.2bn (£850 million) to get a single treatment to the point it can be sold and used in the clinic, could genetic analysis save hundreds of millions of dollars?

Report finds AI, automation and analytics adoption enabling faster trials, streamlined discovery, and lower R&D-to-launch costs across pharma GCCs ...

AI could review data sets to assist clinical scientists ...

Global rare disease policy shifts are reshaping orphan drug development, with major implications for equitable access in the UK, EU and US.

U.S. drug manufacturers are expected to raise prices on at least 350 medications in 2026. The increase coincides with pressure from the Trump administration to lower consumer costs. The detailed ...

As President Donald Trump rolls out his TrumpRx proposal to cut prescription drug prices, economists are raising questions about what happens when prices are capped and whether short-term savings for ...